Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Frequently asked questions
What sector does Active Biotech AB (ACTI) operate in?
Active Biotech AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Active Biotech AB (ACTI) current stock price?
As of the latest data, Active Biotech AB stock price is SEK 5.16, with a previous close of SEK 5.28. Active Biotech AB lost -SEK 0.12 in the last trading session, representing a -2.27% loss.
What is Active Biotech AB (ACTI) current market capitalization?
Active Biotech AB market cap is approximately 136.02 million.
What is Active Biotech AB (ACTI) Earnings Per Share (EPS)?
The trailing EPS is -SEK 2.21.
What is Active Biotech AB (ACTI) EBITDA?
Active Biotech AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.20 million.
Does Active Biotech AB (ACTI) pay dividends?
No. Active Biotech AB does not pay a dividend.
What is Active Biotech AB (ACTI) beta (volatility) score?
Active Biotech AB has a beta of 1.356, suggesting it is more volatile than the market.
